FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145320596> ?p ?o ?g. }

• W2145320596 endingPage "200" @default.
• W2145320596 startingPage "199" @default.
• W2145320596 abstract "In the June 15, 2004 issue of The American Journal of Medicine, using data from the CAPRIE study, 1CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet. 1996; 348: 1329-1339Abstract Full Text Full Text PDF PubMed Scopus (6065) Google Scholar Schleinitz et al, 2Schleinitz M.D. Weiss P. Owens D.K. Clopidogrel versus aspirin for secondary prophylaxis of vascular events a cost-effectiveness analysis.Am J Med. 2004; 116: 797-806Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar claimed that clopidogrel provides an increase in quality-adjusted life expectancy at a reasonable cost in patients who have had an ischemic stroke or who have symptomatic peripheral artery disease.In CAPRIE 1CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet. 1996; 348: 1329-1339Abstract Full Text Full Text PDF PubMed Scopus (6065) Google Scholar clopidogrel instead of aspirin reduced the absolute risk of a new ischemic event (the composite of cardiovascular death, myocardial infarction, or stroke) by a nonsignificant 0.56% per year in patients who had suffered an ischemic stroke. The corresponding absolute risk reduction was 1.15 % in patients with peripheral artery disease (P = 0.003). This means that the number needed to treat after a stroke was around 179 (95% confidence interval [CI]: 80–∞) and the number needed to treat who had peripheral artery disease was approximately 87 (95% CI: 65–300). The cost of clopidogrel is about $2.20 per day in Sweden. Consequently, the yearly expenditure on clopidogrel instead of aspirin to avoid an ischemic event is approximately $142,000 (95% CI: $63,000–∞) after a stroke and $69,000 (95% CI: $52,000–$238,000) in patients with peripheral artery disease.This is evidently not an intelligent way to utilize health care resources. Any real clinical advantages (and side effects) of clopidogrel as a replacement for aspirin must be made clear beyond reasonable doubt before health economic analyses can contribute to our understanding of how to optimize antiplatelet therapy in patients with atherothrombotic disease. The difference between clopidogrel and aspirin was small in CAPRIE, with an absolute risk reduction of only 0.51% for all patients. On the other hand, the costs of clopidogrel are large compared with aspirin. For that reason, let us not have dust blown in our eyes by creative cost-effectiveness analyses. In the June 15, 2004 issue of The American Journal of Medicine, using data from the CAPRIE study, 1CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet. 1996; 348: 1329-1339Abstract Full Text Full Text PDF PubMed Scopus (6065) Google Scholar Schleinitz et al, 2Schleinitz M.D. Weiss P. Owens D.K. Clopidogrel versus aspirin for secondary prophylaxis of vascular events a cost-effectiveness analysis.Am J Med. 2004; 116: 797-806Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar claimed that clopidogrel provides an increase in quality-adjusted life expectancy at a reasonable cost in patients who have had an ischemic stroke or who have symptomatic peripheral artery disease. In CAPRIE 1CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet. 1996; 348: 1329-1339Abstract Full Text Full Text PDF PubMed Scopus (6065) Google Scholar clopidogrel instead of aspirin reduced the absolute risk of a new ischemic event (the composite of cardiovascular death, myocardial infarction, or stroke) by a nonsignificant 0.56% per year in patients who had suffered an ischemic stroke. The corresponding absolute risk reduction was 1.15 % in patients with peripheral artery disease (P = 0.003). This means that the number needed to treat after a stroke was around 179 (95% confidence interval [CI]: 80–∞) and the number needed to treat who had peripheral artery disease was approximately 87 (95% CI: 65–300). The cost of clopidogrel is about $2.20 per day in Sweden. Consequently, the yearly expenditure on clopidogrel instead of aspirin to avoid an ischemic event is approximately $142,000 (95% CI: $63,000–∞) after a stroke and $69,000 (95% CI: $52,000–$238,000) in patients with peripheral artery disease. This is evidently not an intelligent way to utilize health care resources. Any real clinical advantages (and side effects) of clopidogrel as a replacement for aspirin must be made clear beyond reasonable doubt before health economic analyses can contribute to our understanding of how to optimize antiplatelet therapy in patients with atherothrombotic disease. The difference between clopidogrel and aspirin was small in CAPRIE, with an absolute risk reduction of only 0.51% for all patients. On the other hand, the costs of clopidogrel are large compared with aspirin. For that reason, let us not have dust blown in our eyes by creative cost-effectiveness analyses." @default.
• W2145320596 created "2016-06-24" @default.
• W2145320596 creator A5030483444 @default.
• W2145320596 date "2005-02-01" @default.
• W2145320596 modified "2023-09-25" @default.
• W2145320596 title "Creative cost-effectiveness analysis of CAPRIE data— dust in our eyes" @default.
• W2145320596 cites W2077196831 @default.
• W2145320596 cites W311320695 @default.
• W2145320596 doi "https://doi.org/10.1016/j.amjmed.2004.11.013" @default.
• W2145320596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15694910" @default.
• W2145320596 hasPublicationYear "2005" @default.
• W2145320596 type Work @default.
• W2145320596 sameAs 2145320596 @default.
• W2145320596 citedByCount "3" @default.
• W2145320596 countsByYear W21453205962013 @default.
• W2145320596 countsByYear W21453205962019 @default.
• W2145320596 crossrefType "journal-article" @default.
• W2145320596 hasAuthorship W2145320596A5030483444 @default.
• W2145320596 hasConcept C126322002 @default.
• W2145320596 hasConcept C127413603 @default.
• W2145320596 hasConcept C164705383 @default.
• W2145320596 hasConcept C168563851 @default.
• W2145320596 hasConcept C17744445 @default.
• W2145320596 hasConcept C199539241 @default.
• W2145320596 hasConcept C2777628954 @default.
• W2145320596 hasConcept C2777849778 @default.
• W2145320596 hasConcept C2778213512 @default.
• W2145320596 hasConcept C2779473830 @default.
• W2145320596 hasConcept C2780645631 @default.
• W2145320596 hasConcept C44249647 @default.
• W2145320596 hasConcept C500558357 @default.
• W2145320596 hasConcept C71924100 @default.
• W2145320596 hasConcept C78519656 @default.
• W2145320596 hasConcept C83867959 @default.
• W2145320596 hasConceptScore W2145320596C126322002 @default.
• W2145320596 hasConceptScore W2145320596C127413603 @default.
• W2145320596 hasConceptScore W2145320596C164705383 @default.
• W2145320596 hasConceptScore W2145320596C168563851 @default.
• W2145320596 hasConceptScore W2145320596C17744445 @default.
• W2145320596 hasConceptScore W2145320596C199539241 @default.
• W2145320596 hasConceptScore W2145320596C2777628954 @default.
• W2145320596 hasConceptScore W2145320596C2777849778 @default.
• W2145320596 hasConceptScore W2145320596C2778213512 @default.
• W2145320596 hasConceptScore W2145320596C2779473830 @default.
• W2145320596 hasConceptScore W2145320596C2780645631 @default.
• W2145320596 hasConceptScore W2145320596C44249647 @default.
• W2145320596 hasConceptScore W2145320596C500558357 @default.
• W2145320596 hasConceptScore W2145320596C71924100 @default.
• W2145320596 hasConceptScore W2145320596C78519656 @default.
• W2145320596 hasConceptScore W2145320596C83867959 @default.
• W2145320596 hasIssue "2" @default.
• W2145320596 hasLocation W21453205961 @default.
• W2145320596 hasLocation W21453205962 @default.
• W2145320596 hasOpenAccess W2145320596 @default.
• W2145320596 hasPrimaryLocation W21453205961 @default.
• W2145320596 hasRelatedWork W1584895772 @default.
• W2145320596 hasRelatedWork W2049397185 @default.
• W2145320596 hasRelatedWork W2080681036 @default.
• W2145320596 hasRelatedWork W2099734408 @default.
• W2145320596 hasRelatedWork W2136367200 @default.
• W2145320596 hasRelatedWork W2373695000 @default.
• W2145320596 hasRelatedWork W2606030971 @default.
• W2145320596 hasRelatedWork W2926542596 @default.
• W2145320596 hasRelatedWork W95487621 @default.
• W2145320596 hasRelatedWork W2527719101 @default.
• W2145320596 hasVolume "118" @default.
• W2145320596 isParatext "false" @default.
• W2145320596 isRetracted "false" @default.
• W2145320596 magId "2145320596" @default.
• W2145320596 workType "article" @default.